The latest research suggests that the recombinant shingles vaccine may offer additional benefits. It appears to reduce the ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed ...

Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.

GSK has turned to Brooke Shields to get the message out about shingles vaccination. | GSK has turned to Brooke Shields to get ...

UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...

(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage ...

Please see full Prescribing Information for AREXVY. About SHINGRIX (Recombinant Zoster Vaccine or RZV) SHINGRIX is a non-live, recombinant subunit vaccine indicated for the prevention of shingles in ...